The role of TRAIL (TNFSF10) expression as a predictor of clinical outcome in patients with metastatic RCC treated with inhibitory agents for tyrosine kinase and/or mTOR in the Cancer Institute Hospital was investigated. This evidence concerns the gene MTOR and renal cell carcinoma.